ロード中...
Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common adult leukemia, with an overall poor prognosis. New agents targeting various receptors may improve treatment outcomes and overall survival. FMS-like tyrosine kinase 3 (FLT3) is a targetable mutation occurring in one third of AML patients. It contribute...
保存先:
| 出版年: | J Adv Pract Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Harborside Press LLC
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7517771/ https://ncbi.nlm.nih.gov/pubmed/33542854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.1.7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|